NCT01518465.

Study name	Dalteparin, lenalidomide, and low‐dose dexamethasone in treating patients with previously untreated multiple myeloma
Methods	Randomised, open‐label, pilot phase II trial
Participants	Patients with a diagnosis of active multiple myeloma requiring treatment
Interventions	Intervention: dalteparin 5000 IU SC once daily on days 1–28; lenalidomide on days 1–21; and low‐dose dexamethasone on days 1, 8, 15, and 22 Control: dalteparin 200 IU/kg SC on days 1–21
Outcomes	Primary outcome: number of participants who experienced grade 4 haemorrhage regardless of attribution, or grade 3 haemorrhage that is possibly, probably, or definitely attributable to dalteparin Secondary outcome: toxicities observed at each dose level
Starting date	January 2012
Contact information	Ann Mohrbacher
Notes	NCT01518465 The study status in ClinicalTrials.gov is "terminated" due to insufficient accrual.